Johnson & Johnson (JNJ) Announces SPRAVATO Approved in the U.S.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Raymond James Reiterates Outperform Rating on Johnson & Johnson (JNJ)
January 22, 2025 8:15 AM ESTRaymond James analyst Jayson Bedford reiterated an Outperform rating and $170.00 price target on Johnson & Johnson (NYSE: JNJ)
The analyst comments "Quick take: 4Q results were solid with a 1% revenue beat and a 3% EPS beat. The revenue upside was driven by Innovative Medicine... More
